GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » Volatility

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Volatility : 70.70% (As of Jun. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-06-15), MyMD Pharmaceuticals's Volatility is 70.70%.


Competitive Comparison of MyMD Pharmaceuticals's Volatility

For the Biotechnology subindustry, MyMD Pharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MyMD Pharmaceuticals's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where MyMD Pharmaceuticals's Volatility falls into.



MyMD Pharmaceuticals  (NAS:MYMD) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyMD Pharmaceuticals  (NAS:MYMD) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


MyMD Pharmaceuticals Volatility Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.
Executives
Paul Rivard officer: EVP of Operations, GC C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams 10 percent owner 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin officer: Chief Scientific Officer C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne director C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle director POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr director, officer: President, Chief Med. Officer C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes officer: Interim CFO 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Headlines

From GuruFocus